320 Charlson comorbidity index as a factor impacting survival among ovarian cancer patients – results from a systematic review

Introduction/BackgroundThere are a few scattered primary level studies from various regions of the globe proving impact of co-morbidities on survival in ovarian cancer patients. In last 20 years, there has been improvement in survival among ovarian cancer patients. Radical surgical approaches and ad...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of gynecological cancer Vol. 30; no. Suppl 4; pp. A66 - A67
Main Authors Asthana, Smita, Modi, Rahul
Format Journal Article
LanguageEnglish
Published Oxford BMJ Publishing Group LTD 01.12.2020
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Introduction/BackgroundThere are a few scattered primary level studies from various regions of the globe proving impact of co-morbidities on survival in ovarian cancer patients. In last 20 years, there has been improvement in survival among ovarian cancer patients. Radical surgical approaches and advancements in chemotherapeutic agents have primarily contributed for same. Pre-existing uncontrolled co-morbidities impact ovarian cancer survival directly and indirectly. This affects the performance status of the patient leading to delay in treatment or aversion from radical surgical approaches thereby not achieving the goal of optimal treatment. It may also lead to a less aggressive chemotherapeutic modifications of using lower doses or single agent chemotherapy. The objective of this study was to systematically review the literature and summarize prevalence of various comorbidities with evaluation of impact of the Charlson Co-morbidity Index (CCI) on survival in ovarian cancer patients.MethodologyPrimary studies were identified by following a defined search strategy on the prevalence of co-morbidity and survival pattern among ovarian cancer patients. This study has been conducted in accordance with PRISMA guidelines for systematic review. Co-morbidity assessment in the included studies had been done through the Charlson Co-morbidity Index (CCI) tool. Qualitative summarization of data from included studies for prevalence of various co-morbidities and influence of CCI score on survival in ovarian cancer patients has been performed.ResultsCommon co-morbidities prevalent in ovarian cancer patients were hypertension (11% to 26%), cardio vascular disease (4.5% to 12%) and diabetes (2.5% to 8.3%). Less commonly occurring co-morbidities were liver disease, renal disease, neurological problems and collagen vascular disease. Majority of ovarian cancer patients lie in CCI score 0 (68% - 76%). The range for one year% survival for CCI score 0 was 73 to 80%, for CCI score 1–2 : 58 to 71% and CCI score 2+ : 43 to 53%. The range five year% survival for CCI score 0 was 37 to 43%, for CCI score 1–2 : 24 to 30% and CCI score 2+ : 12 to 23%.ConclusionCo-morbidities plays an important role in survival outcomes among ovarian cancer patients. Overall one year% and five year% survival decreases with increase in the CCI index score.DisclosuresThe authors have no conflict of interest.
AbstractList Introduction/BackgroundThere are a few scattered primary level studies from various regions of the globe proving impact of co-morbidities on survival in ovarian cancer patients. In last 20 years, there has been improvement in survival among ovarian cancer patients. Radical surgical approaches and advancements in chemotherapeutic agents have primarily contributed for same. Pre-existing uncontrolled co-morbidities impact ovarian cancer survival directly and indirectly. This affects the performance status of the patient leading to delay in treatment or aversion from radical surgical approaches thereby not achieving the goal of optimal treatment. It may also lead to a less aggressive chemotherapeutic modifications of using lower doses or single agent chemotherapy. The objective of this study was to systematically review the literature and summarize prevalence of various comorbidities with evaluation of impact of the Charlson Co-morbidity Index (CCI) on survival in ovarian cancer patients.MethodologyPrimary studies were identified by following a defined search strategy on the prevalence of co-morbidity and survival pattern among ovarian cancer patients. This study has been conducted in accordance with PRISMA guidelines for systematic review. Co-morbidity assessment in the included studies had been done through the Charlson Co-morbidity Index (CCI) tool. Qualitative summarization of data from included studies for prevalence of various co-morbidities and influence of CCI score on survival in ovarian cancer patients has been performed.ResultsCommon co-morbidities prevalent in ovarian cancer patients were hypertension (11% to 26%), cardio vascular disease (4.5% to 12%) and diabetes (2.5% to 8.3%). Less commonly occurring co-morbidities were liver disease, renal disease, neurological problems and collagen vascular disease. Majority of ovarian cancer patients lie in CCI score 0 (68% - 76%). The range for one year% survival for CCI score 0 was 73 to 80%, for CCI score 1–2 : 58 to 71% and CCI score 2+ : 43 to 53%. The range five year% survival for CCI score 0 was 37 to 43%, for CCI score 1–2 : 24 to 30% and CCI score 2+ : 12 to 23%.ConclusionCo-morbidities plays an important role in survival outcomes among ovarian cancer patients. Overall one year% and five year% survival decreases with increase in the CCI index score.DisclosuresThe authors have no conflict of interest.
Author Asthana, Smita
Modi, Rahul
Author_xml – sequence: 1
  givenname: Smita
  surname: Asthana
  fullname: Asthana, Smita
  organization: All India Institute of Medical Sciences (Aiims), Rishikesh; Gynaecological Oncology
– sequence: 2
  givenname: Rahul
  surname: Modi
  fullname: Modi, Rahul
  organization: All India Institute of Medical Sciences (Aiims), Rishikesh; Gynaecological Oncology
BookMark eNotUE1Lw0AQXaSCbfUPeFrwHN2PbJo9SqlVKPSggrcw2WzqliQbd5Nob0XwF_gP-0vcUpnDvJl584Z5EzRqbKMRuqbkllKe3JntRkWMMBItnpfr0JNnaEwFExGNeToKmMRplEr6doEm3m8JIZIROUbfnJHD_mf-Dq7ytsHK1tblpjDdDpum0F8YPAZcguqsw6ZuAzDNBvveDWaACkNtQ2kHcAbCOjRKO9xCZ3TTeXzY_2KnfV8FXDpbBym_852uA0GFyWD05yU6L6Hy-uo_T9Hrw-Jl_hit1sun-f0qyiklMhJA8_CLKsqZ5CrhXPE0jkWRsyRJCykELSnERaryGSuTMpZ5AVBymXKWCwGaT9HNSbd19qPXvsu2tndNOJkxIZhMQ5DAik6svN5mrTM1uF1GSXa0OTvanB1tzo42h57kf7qxdxs
ContentType Journal Article
Copyright Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Copyright_xml – notice: Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
– notice: 2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
DBID 3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
PQEST
PQQKQ
PQUKI
PRINS
DOI 10.1136/ijgc-2020-ESGO.119
DatabaseName ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
DatabaseTitle ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest One Academic
ProQuest Central (Alumni)
DatabaseTitleList ProQuest One Academic Eastern Edition

Database_xml – sequence: 1
  dbid: 7X7
  name: ProQuest_Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1525-1438
EndPage A67
ExternalDocumentID ijgc
GroupedDBID ---
.3N
.Z2
0R~
1OC
29J
31~
36B
4.4
53G
5GY
5VS
7X7
8-1
8FI
8FJ
AAHLL
AAKAS
AARTV
ABBUW
ABJNI
ABUWG
ABXVJ
ABZAD
ACDDN
ACEWG
ACGFO
ACGFS
ACWDW
ACWRI
ACXNZ
ACXQS
ADZCM
AENEX
AFBPY
AFEBI
AFKRA
AFTRI
AFZJQ
AGINI
AHEFC
AIZYK
AJAOE
AJNYG
AJYBZ
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AWKKM
BENPR
BFHJK
BQLVK
CAG
CCPQU
CO8
COF
CS3
CXRWF
DC6
DCZOG
E.X
EBS
EJD
EX3
F5P
FL-
FYUFA
FZ0
HAJ
HMCUK
HZI
HZ~
IHE
IN~
KD2
L-C
LH4
LW6
O9-
OCUKA
OHYEH
ORVUJ
OUVQU
OVD
OXXIT
P2P
RMJ
ROL
S4S
TEORI
UDS
UKHRP
V2I
W3M
W99
WOW
X3V
X3W
YUY
3V.
7XB
8FK
K9.
PQEST
PQQKQ
PQUKI
PRINS
ID FETCH-LOGICAL-b1109-5a1b438cdf793c633c38445db2668d9551f1a4d8cb72f6f49bdaaf39832b55ae3
IEDL.DBID 7X7
ISSN 1048-891X
IngestDate Thu Oct 10 20:02:37 EDT 2024
Tue Nov 26 19:18:13 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Suppl 4
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b1109-5a1b438cdf793c633c38445db2668d9551f1a4d8cb72f6f49bdaaf39832b55ae3
OpenAccessLink https://ijgc.bmj.com/content/ijgc/30/Suppl_4/A66.2.full.pdf
PQID 2552989890
PQPubID 5161120
ParticipantIDs proquest_journals_2552989890
bmj_primary_10_1136_ijgc_2020_ESGO_119
PublicationCentury 2000
PublicationDate 20201200
20201201
PublicationDateYYYYMMDD 2020-12-01
PublicationDate_xml – month: 12
  year: 2020
  text: 20201200
PublicationDecade 2020
PublicationPlace Oxford
PublicationPlace_xml – name: Oxford
PublicationTitle International journal of gynecological cancer
PublicationYear 2020
Publisher BMJ Publishing Group LTD
Publisher_xml – name: BMJ Publishing Group LTD
SSID ssj0009209
Score 2.3249993
Snippet Introduction/BackgroundThere are a few scattered primary level studies from various regions of the globe proving impact of co-morbidities on survival in...
SourceID proquest
bmj
SourceType Aggregation Database
Publisher
StartPage A66
SubjectTerms Morbidity
Ovarian cancer
Systematic review
Title 320 Charlson comorbidity index as a factor impacting survival among ovarian cancer patients – results from a systematic review
URI https://ijgc.bmj.com/content/30/Suppl_4/A66.2.full
https://www.proquest.com/docview/2552989890
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8QwEA6ugngRn_gmB_FW3DZpm55EZXURfKAu9FbyaGVFd3XrehbBX-A_9Jf4Jc2yB8FbSGkpM5OZ70syM4Ts24IiOooEaEkCgsIzFYBGwJZVFqWVNJVx1fkvr5Juj1_kce433Gp_rXLiE52jNkNt98gPAX0j1-uwffTyGtiuUfZ01bfQaJG5MEIohz2neTotuttc8QDjEIHIwnySNMOSw_7jg4aFgDt17s6vMQeI2VLPj39csoszZ0tk0QNEetxodJnMlIMVMn_pj8BXySeL2j8fX-6YHFiZ4u-HI9U3QNPUlT6ksqaSNn10aJMEifBE6zGcAsyKuvZCdPgOkizxutX6iPryqjX9-fimYODjJ4xt6gk-NS32TJtElzXSO-vcn3YD30ghULagaBDLUHEmtKmwGnXCmGaC89goRGdhMoCmKpTcCK3SqEoqKMxIWbEMq13FsSzZOpkdDAflhk3xFolQWSykLjkGKm0rpSU4LZBXGvNNcgApFi9NqYzCUQyWFFbchRV3YcWNuWyT7EwEXfhlUxdTJW_9_3ibLDjluXslO2T2bTQud4EO3tSeM4E9MnfSubq5_QUJi7wT
link.rule.ids 314,780,784,12056,21388,27924,27925,31719,33744,43310,43805,73745,74302
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3LSgMxFA1aQd2IT3xUzULcDbbzamYlKq310SraQndDHjNS0bZ2WtdF8Av8w36JJ5mULgR3IcMMw703yTlJ7rmEnGhBEem6DLQkBEHxI-GARiCWReRWUq5SZdT5G82w3vZvO0HHbrhl9lrlbE40E7XqS71Hfgbo65pah6XzwYejq0bp01VbQmORLGnl9KBAli6rzcenuexufskDnIM5LCp3ZmkzXnjWfX2RiBGwp-rz9QP6ADIXxfvrn0nZrDS1dbJmISK9yH26QRaS3iZZbthD8C3y5bml6eTbHJQDLVP8f38ougp4mhrxQ8ozymleSYfmaZBYoGg2xrSAwKKmwBDtf4Imc7yu_T6kVmA1o9PJDwUHH7-hrZNP8Km53DPNU122SbtWbV3VHVtKwRFaUtQJeFnAQlKlGI8y9DzpMd8PlMD6zFQE2JSWua-YFBU3DVO4THGeehHGuwgCnng7pNDr95JdneTNQiaigHGZ-GiISkkIycFqgb0qgb9HTmHFeJCLZcSGZHhhrM0da3PH2tzoi_ZIcWbo2A6cLJ67ef__x8dkpd5q3Mf3N827A7JqHGlumRRJYTQcJ4fACiNxZAPiF1Skvs8
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEF60QvEiPrE-9yDeQttskm5O4qP1XUUt9Bb2kUiLttpYzyL4C_yH_hK_3WzpQfAWNiSQmdmZ-bIz3xCyZwhFlO9zwJIIACWIpQcYAVuWsd_IhM60Zee_bkdnneCiG3Zd_VPuyionPtE6aj1U5h95Famvb2cd1qqZK4u4PWkdvLx6ZoKUOWl14zRmyRyiYs0vkbmjZvv2bkrBWxR8AH9wj8f17qSFhkXVXv9RwV6ApJr3pzdYQ8I5K5_7fxy0jTqtRbLg0kV6WOh3icykg2VSvnYH4ivkk_m1n48ve2iOzJniW4Yj2dPIraklQqQip4IWU3Vo0RKJYEXzMVwEjIzaYUN0-A7ILPC4sYERdWSrOf35-KbA4-MnXJtGFLxqSv1Mi7aXVdJpNR-Ozzw3VsGThl7UC0VdBowrnWFvqogxxXgQhFoiVnMdI4XK6iLQXMmGn0UZ1KeFyFiMvS_DUKRsjZQGw0G6bhq-ecRlHHKh0gAXslGTUgkgXORhjTCokH1IMXkpiDMSCzhYlBhxJ0bciRE31uIK2ZoIOnGbKE-mKt_4__YuKcMWkqvz9uUmmbd6tAUnW6T0Nhqn20gb3uSOs4df62XC_A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=320%E2%80%85Charlson+comorbidity+index+as+a+factor+impacting+survival+among+ovarian+cancer+patients+%E2%80%93+results+from+a+systematic+review&rft.jtitle=International+journal+of+gynecological+cancer&rft.au=Asthana%2C+Smita&rft.au=Modi%2C+Rahul&rft.date=2020-12-01&rft.pub=BMJ+Publishing+Group+LTD&rft.issn=1048-891X&rft.eissn=1525-1438&rft.volume=30&rft.issue=Suppl+4&rft.spage=A66&rft.epage=A67&rft_id=info:doi/10.1136%2Fijgc-2020-ESGO.119&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1048-891X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1048-891X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1048-891X&client=summon